期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 44, 期 10, 页码 2883-2886出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.44.10.2883-2886.2000
关键词
-
The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Overall, ravuconazole (MIC at which 90% of the isolates are inhibited [MIC90], 0.25 mu g/ml) was more active than either itraconazole (MIC90, 0.5 mu g/ml) or fluconazole (MIC90, 8 mu g/ml). Among the isolates inhibited by greater than or equal to 16 mu g of fluconazole/ml, 90.2% were inhibited by less than or equal to 1 mu g of ravuconazole/ml. On the basis of our findings and the favorable pharmacokinetic properties of ravuconazole, we suggest that ravuconazole may be useful for the treatment of infectious diseases due to C. neoformans and that further clinical studies to confirm these promising in vitro results are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据